| Send2Press.com • Today is Monday, February 13, 2012 | A Member of the Neotrope News Network |  |
|
|
NEWS ARCHIVES : U.S. and World News :
Medical :
Drugs and Pharmaceuticals
News
|
Press Release:
Advanced Phase I and Phase II Studies of Targeted Gene Delivery Confirm That Rexin-G Impacts Survival in Chemotherapy-resistant Bone and Soft Tissue Sarcoma (ASCO 2010)
SAN MARINO, Calif., June 1 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation (www.epeiusbiotech.com) today announces the results of the clinical trial entitled "Advanced Phase I/II Evaluation of Tumor-Targeted Gene Delivery: Intravenous Rexin-G as Stand Alone Therapy for Chemotherapy-resistant Bone and Soft Tissue Sarcoma" at the ASCO Annual Meeting on June 8, 2010. The presentation will be discussed by Dr. Kristen N. Ganjoo, Stanford University Medical Center, Palo Alto CA.STUDY SUMMARY: The goals of the study were to evaluate the over-all safety and efficacy of intravenous infusions of Rexin-G, a tumor-targeted retrovector bearing a cytocidal anti-cyclin G1 construct, in chemo-therapy-resistant bone and soft tissue sarcoma. A Phase II "run-in" component was integrated by adaptive design by continuing treatment if the patient had Grade 1 or less toxicity. Thirty-six patients received escalating doses of Rexin-G intravenously three times a week for four weeks. Analysis of safety showed no dose-limiting toxicity and no cumulative toxicity in patients treated with Rexin-G monotherapy for up to 2 years. Analysis of efficacy revealed a dose-dependent relationship between progression-free survival/overall survival and Rexin-G dosage (p = 0.02 and 0.002 respectively) which was significant at the 5% statistical level by the log-rank test. Median survival was 11.5 months and one-year survival was 40% in the high-dose groups. These findings indicate that intravenous Rexin-G is safe and well-tolerated with no cumulative toxicity, and that Rexin-G controls tumor growth, and prolongs progression-free survival and over-all survival times in a dose-dependent manner in patients with chemotherapy resistant bone and soft tissue sarcoma. About Epeius Biotechnologies: Epeius Biotechnologies Corporation (www.epeiusbiotech.com) is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its lead products, Rexin-G and Reximmune-C, and its high-performance gene delivery systems. To learn more about these agents and/or ongoing clinical trials, please contact Dr. Erlinda M. Gordon at egordon_@_epeiusbiotech.com.
NEWS SOURCE: Epeius Biotechnologies Corporation
Send2Press® is the originating wire service for this story. Terms of Use. © Epeius Biotechnologies Corporation. All trademarks acknowledged.
THE CONTENT OF THE ABOVE PRESS RELEASE WAS PROVIDED BY THE NEWS SOURCE (Epeius Biotechnologies Corporation), WHO IS SOLELY RESPONSIBLE FOR ITS ACCURACY. FOR QUESTIONS ABOUT THIS STORY CONTACT THE NEWS SOURCE AND NOT THIS WEBSITE.
Journalist Resources:
Download original press release as issued including media contact information for Epeius Biotechnologies Corporation.
Additional News Releases on Similar Topics:
|
Subscribe to Send2Press®
Daily News Releases by E-Mail
Follow Send2Press on Social Sites: 
Additional News from
Epeius Biotechnologies Corporation : » Epeius Biotechnologies Awarded Federal Grant Advancing Tumor-Targeted Cancer Therapy
|
||||||||||||||||||||||||||
View our news channels by industry topics, by U.S. States, or by selected U.S. Cities:
|
Terms of Use and License
This "article format" version of the issued press release is Copr. © 1983-2012 Neotrope/Send2Press. You may freely link to this article version of the press release or may use the release text as the basis for an original article or news posting. If the content is copied verbatim via a scraping or copy/paste method, the news item must be properly "attributed" to Send2Press® Newswire as the originating wire service for this story (may not be posted on ANY site selling/offering SEO or PR services, newswire services, or adult content!). |
DISCLAIMER: the above press release content is believed accurate but not guaranteed, and is based on business news supplied by the source. The noted source is solely responsible for its accuracy. Financial/Stock news may contain forward looking statements. Neotrope/Send2Press (this website) makes no claims of accuracy or suitability for any purpose. Any opinions expressed by representatives of company(s) mentioned in news and profiles are solely those of the person indicated, and do not reflect any opinion or policy of Neotrope® or Send2Press. Your use of any information contained herein is done solely at your own risk, and you are fully responsible for using any information herein, or on sites mentioned or linked to in the article. All trademarks acknowledged.
REFERENCES: Advanced Phase I and Phase II Studies of Targeted Gene Delivery Confirm That Rexin-G Impacts Survival in Chemotherapy-resistant Bone and Soft Tissue Sarcoma (ASCO 2010), Epeius Biotechnologies Corporation, clinical trial, Advanced Phase I/II Evaluation of Tumor-Targeted Gene Delivery, Intravenous Rexin-G as Stand Alone Therapy for Chemotherapy-resistant Bone and Soft Tissue Sarcoma, at the ASCO Annual Meeting, press release, Jun 1, 2010. |
|
THIS PAGE MEDIA READS (by media and public, as of today): 2672 times (2 today, 3 this week, 12 this month, 35 this year)
Site Design and Content is Copr. © 1983 - 2011 Neotrope® - All rights reserved. Send2Press® is a reg. trademark and service mark of NEOTROPE.
Press Release Writing | About Send2Press | Meet Our Staff | Contact Us | Our Services | Help Desk | Legal | Privacy | How-To Articles | RSS Feeds | Journalist Tools | Client eMediaKits | Headline Feeds | Podcast | PR News Channels | Daily News Desk | Success Stories | PRTRax™ Reader Tracking | Targeted News Distribution | Internet Marketing Services | Order PR Services | Terms of Service (TOS)